Australia's Antisense Therapeutics falls on discounted raise to fund therapy study

Percheron Therapeutics

20/07/2023 03:10

** Shares of Antisense Therapeutics  ANP.AX  fall as much as
11.5% to A$0.054
    ** The biotechnology co proposes share purchase plan to
raise A$1.5 mln ($1.02 mln) to fund its international phase
study of its ATL1102 therapy to treat Duchenne muscular
dystrophy 
    ** Issue price of A$0.05 per share represents an 18% to
stock's last close on July 19
    ** More than 1.6 mln shares change hands, compared with the
30-day average volume of about 878,000 shares
    ** Stock down 37.1% this year, as of last close
 
    ($1 = 1.4641 Australian dollars)

 (Reporting by Jaskiran Singh in Bengaluru)
 ((Jaskiran.Singh@thomsonreuters.com;))